Junqi Guo^1,2, Yun Yang^1,2, Wei Zhao^1,2, Zhonghai Yan³, Xia Yang⁴, Yunfei Yan^1,2, Ruimin Hao^1,2, Jinxia Hu^1,2,*, Fei Jiao^1,2,*

BIOCELL, Vol.49, No.9, pp. 1797-1797, 2025, DOI:10.32604/biocell.2025.071013 - 25 September 2025

Abstract This article has no abstract. More >

Anjali Kariyarath Valappil^1,#, Reshmi Akter^2,#, Muhammad Awais², Dong Uk Yang³, Daehyo Jung², Li Ling⁴, Eun Kim⁵, Kyu Hyeong Yoon⁵, Yoon Ok Lee⁵, Deok Chun Yang^1,2,4,*

BIOCELL, Vol.49, No.9, pp. 1771-1795, 2025, DOI:10.32604/biocell.2025.069145 - 25 September 2025

Abstract Objectives: The phytochemical investigation of traditional herbal medicines holds significant promise for modern drug discovery, particularly in cancer therapy. This study aimed to evaluate the cytotoxicity, apoptosis induction, and immune-modulatory activities of extracts from three herbal medicines with historical use in traditional medicine—Acanthopanax sessiliflorus, Phragmites communis, and Pinus densiflora, as well as their combined extract (GMAS 01/COM), on human lung cancer cells (A549) and normal cell lines, including murine macrophages (RAW 264.7) and human keratinocytes (HaCaT). Methods: Plant extracts were prepared using aqueous extraction, sonication, and rotary evaporation. The total phenolic and flavonoid contents were quantified using the… More >

Oncology Research Editorial Offfce

Oncology Research, Vol.33, No.9, pp. 2599-2599, 2025, DOI:10.32604/or.2025.071884 - 28 August 2025

Abstract This article has no abstract. More >

Xi Qin^1,#, Yulan Liu^1,#, Lin Zhu², Yunyan Mo¹, Jing Zhang³, Zhuchun Jiang⁴, Dongning Huang⁵, Xinrong Hu⁶, Jingzhang Li⁷, Quanfang Chen⁸, Feng Xue^1,*

Oncology Research, Vol.33, No.9, pp. 2451-2462, 2025, DOI:10.32604/or.2025.064119 - 28 August 2025

Abstract Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases. Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint. Adverse events… More >

Shengmin Li¹, Kejian Shi¹, Ying Wang^2,*, Yi Zhang^1,*

Oncology Research, Vol.33, No.9, pp. 2435-2449, 2025, DOI:10.32604/or.2025.063812 - 28 August 2025

Abstract Objectives: Lung cancer represents a major global healthcare challenge, characterized by high annual incidence and mortality rates worldwide. Although targeted therapies for lung cancer have advanced, treatment outcomes for advanced-stage patients remain suboptimal. This investigation examines the role of the translocase of the inner mitochondrial membrane (TIMM)8A-TIMM13 complex in lung cancer and evaluates its potential as a novel therapeutic target. Methods: A co-immunoprecipitation (Co-IP) assay was conducted to verify the interaction between TIMM8A and TIMM13. Differential gene expression analysis of TIMM8A or TIMM13 was executed using the TNMplot database, with survival estimates derived from the… More >

KHANH TOAN NGUYEN^*, THI HUONG PHAM, VAN LAM NGO, VAN TUAN BUI, VAN NHAT NGUYEN, THI PHUONG THAO NGUYEN, THI KHANH HA NGUYEN, THI THUY VAN NGUYEN

Oncology Research, Vol.33, No.7, pp. 1667-1677, 2025, DOI:10.32604/or.2025.061905 - 26 June 2025

Abstract Aims: The study aimed to evaluate the effectiveness and adverse events of tyrosine kinase inhibitors (TKIs) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: A retrospective study on advanced NSCLC patients with EGFR mutations treated with TKIs as a first-line therapy at Nghe An Oncology Hospital, Vietnam between January 2017 and August 2023. The primary endpoints included objective response rate, progression-free survival, and tolerability. The secondary endpoint was overall survival. Results: A total of 211 patients received first-line treatment with Erlotinib (n = 74), Gefitinib (n… More >

YUZHENG LI^1,2, LILI YU¹, SHIYAO ZHOU¹, HUA ZHOU^2,3,*, QIBIAO WU^1,2,*

Oncology Research, Vol.33, No.6, pp. 1363-1376, 2025, DOI:10.32604/or.2025.059311 - 29 May 2025

Abstract Background: Non-small cell lung cancer (NSCLC) involves complex alterations in the epidermal growth factor receptor (EGFR) signaling pathway. This study aims to integrate multimodal omics analyses to evaluate and enhance EGFR-targeted therapies. Methods: We reviewed and synthesized omics data—including genomics, transcriptomics, proteomics, epigenomics, and metabolomics data—related to the EGFR pathway in NSCLC, examined the clinical outcomes of current therapies and proposed new treatment strategies. Results: Integrated omics analyses revealed the multifaceted role of EGFR in NSCLC. Transcriptomic analysis revealed gene expression alterations due to EGFR mutations, with upregulation of oncogenes and downregulation of tumor suppressors. Proteomics More >

XIAOBI HUANG¹, CHUNYUAN CHEN², YONGYANG CHEN¹, HONGLIAN ZHOU¹, YONGHUA CHEN¹, ZHONG HUANG¹, YULIU XIE¹, BAIYANG LIU¹, YUDONG GUO¹, ZHIXIONG YANG¹, GUANGHUA CHEN³, WENMEI SU^1,4

Oncology Research, Vol.33, No.5, pp. 1249-1250, 2025, DOI:10.32604/or.2024.061822 - 18 April 2025

Abstract This article has no abstract. More >

JIAHUI WANG^1,#, HONGCHENG GE^2,3,#, ZHENGYUAN YU^1,*, LINGZHI WU^1,*

Oncology Research, Vol.33, No.5, pp. 1033-1054, 2025, DOI:10.32604/or.2024.058256 - 18 April 2025

Abstract Lung cancer is a common cause of cancer-related death globally. The majority of lung cancer patients initially benefit from chemotherapy and immunotherapy. However, as the treatment cycle progresses and the disease evolves, the emergence of acquired resistance leads to treatment failure. Many researches have shown that non-coding RNAs (ncRNAs) not only influence lung cancer progression but also act as potential mediators of immunotherapy and chemotherapy resistance in lung cancer, mediating drug resistance by regulating multiple targets and pathways. In addition, the regulation of immune response by ncRNAs is dualistic, forming a microenvironment for inhibits/promotes More >

Majdi Rawashdeh^1,2,*, Muath A. Obaidat³, Meryem Abouali⁴, Dhia Eddine Salhi⁵, Kutub Thakur⁶

CMES-Computer Modeling in Engineering & Sciences, Vol.143, No.1, pp. 1129-1155, 2025, DOI:10.32604/cmes.2025.063765 - 11 April 2025

Abstract Cancer is a formidable and multifaceted disease driven by genetic aberrations and metabolic disruptions. Around 19% of cancer-related deaths worldwide are attributable to lung and colon cancer, which is also the top cause of death worldwide. The malignancy has a terrible 5-year survival rate of 19%. Early diagnosis is critical for improving treatment outcomes and survival rates. The study aims to create a computer-aided diagnosis (CAD) that accurately diagnoses lung disease by classifying histopathological images. It uses a publicly accessible dataset that includes 15,000 images of benign, malignant, and squamous cell carcinomas in the lung.… More >